vs
EQT Corporation（EQT）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
EQT Corporation的季度营收约是硕腾的1.4倍（$3.4B vs $2.4B），EQT Corporation净利率更高（44.0% vs 25.3%，领先18.7%），EQT Corporation同比增速更快（94.2% vs 3.0%），EQT Corporation自由现金流更多（$1.9B vs $732.0M），过去两年EQT Corporation的营收复合增速更高（94.9% vs 4.4%）
EQT公司是总部位于美国宾夕法尼亚州匹兹堡的领先独立天然气勘探生产企业，主要在阿巴拉契亚盆地运营，生产天然气、天然气液体和原油，为北美市场的民用、商用、工业及发电领域供应能源。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
EQT vs ZTS — 直观对比
营收规模更大
EQT
是对方的1.4倍
$2.4B
营收增速更快
EQT
高出91.2%
3.0%
净利率更高
EQT
高出18.7%
25.3%
自由现金流更多
EQT
多$1.2B
$732.0M
两年增速更快
EQT
近两年复合增速
4.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.4B | $2.4B |
| 净利润 | $1.5B | $603.0M |
| 毛利率 | — | 70.2% |
| 营业利润率 | 60.3% | 31.9% |
| 净利率 | 44.0% | 25.3% |
| 营收同比 | 94.2% | 3.0% |
| 净利润同比 | 514.5% | 3.8% |
| 每股收益（稀释后） | $2.36 | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EQTZTS
| Q1 26 | $3.4B | — | ||
| Q4 25 | $2.4B | $2.4B | ||
| Q3 25 | $2.0B | $2.4B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | $1.7B | $2.2B | ||
| Q4 24 | $1.6B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $889.5M | $2.4B |
净利润EQTZTS
| Q1 26 | $1.5B | — | ||
| Q4 25 | $677.1M | $603.0M | ||
| Q3 25 | $335.9M | $721.0M | ||
| Q2 25 | $784.1M | $718.0M | ||
| Q1 25 | $242.1M | $631.0M | ||
| Q4 24 | $418.4M | $581.0M | ||
| Q3 24 | $-300.8M | $682.0M | ||
| Q2 24 | $9.5M | $624.0M |
毛利率EQTZTS
| Q1 26 | — | — | ||
| Q4 25 | 83.8% | 70.2% | ||
| Q3 25 | 80.7% | 71.5% | ||
| Q2 25 | 84.8% | 73.6% | ||
| Q1 25 | 78.3% | 72.0% | ||
| Q4 24 | 76.2% | 69.5% | ||
| Q3 24 | 65.7% | 70.6% | ||
| Q2 24 | 38.9% | 71.7% |
营业利润率EQTZTS
| Q1 26 | 60.3% | — | ||
| Q4 25 | 42.5% | 31.9% | ||
| Q3 25 | 30.8% | 37.0% | ||
| Q2 25 | 44.3% | 36.7% | ||
| Q1 25 | 28.5% | 36.5% | ||
| Q4 24 | 48.1% | 31.6% | ||
| Q3 24 | -22.0% | 36.6% | ||
| Q2 24 | 0.3% | 33.0% |
净利率EQTZTS
| Q1 26 | 44.0% | — | ||
| Q4 25 | 28.4% | 25.3% | ||
| Q3 25 | 17.1% | 30.0% | ||
| Q2 25 | 30.7% | 29.2% | ||
| Q1 25 | 13.9% | 28.4% | ||
| Q4 24 | 25.8% | 25.1% | ||
| Q3 24 | -23.4% | 28.6% | ||
| Q2 24 | 1.1% | 26.4% |
每股收益（稀释后）EQTZTS
| Q1 26 | $2.36 | — | ||
| Q4 25 | $1.08 | $1.37 | ||
| Q3 25 | $0.53 | $1.63 | ||
| Q2 25 | $1.30 | $1.61 | ||
| Q1 25 | $0.40 | $1.41 | ||
| Q4 24 | $0.74 | $1.29 | ||
| Q3 24 | $-0.54 | $1.50 | ||
| Q2 24 | $0.02 | $1.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $326.6M | — |
| 总债务越低越好 | $507.5M | — |
| 股东权益账面价值 | $28.8B | $3.3B |
| 总资产 | $41.7B | $15.5B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资EQTZTS
| Q1 26 | $326.6M | — | ||
| Q4 25 | $110.8M | — | ||
| Q3 25 | $235.7M | $2.1B | ||
| Q2 25 | $555.5M | $1.4B | ||
| Q1 25 | $281.8M | $1.7B | ||
| Q4 24 | $202.1M | $2.0B | ||
| Q3 24 | $89.0M | $1.7B | ||
| Q2 24 | $30.0M | $1.6B |
总债务EQTZTS
| Q1 26 | $507.5M | — | ||
| Q4 25 | $7.8B | — | ||
| Q3 25 | $8.2B | — | ||
| Q2 25 | $8.3B | — | ||
| Q1 25 | $8.4B | — | ||
| Q4 24 | $9.3B | — | ||
| Q3 24 | $13.8B | — | ||
| Q2 24 | $5.0B | — |
股东权益EQTZTS
| Q1 26 | $28.8B | — | ||
| Q4 25 | $23.8B | $3.3B | ||
| Q3 25 | $23.2B | $5.4B | ||
| Q2 25 | $21.4B | $5.0B | ||
| Q1 25 | $20.7B | $4.7B | ||
| Q4 24 | $20.6B | $4.8B | ||
| Q3 24 | $20.3B | $5.2B | ||
| Q2 24 | $15.1B | $5.0B |
总资产EQTZTS
| Q1 26 | $41.7B | — | ||
| Q4 25 | $41.8B | $15.5B | ||
| Q3 25 | $41.2B | $15.2B | ||
| Q2 25 | $39.7B | $14.5B | ||
| Q1 25 | $39.7B | $14.1B | ||
| Q4 24 | $39.8B | $14.2B | ||
| Q3 24 | $39.9B | $14.4B | ||
| Q2 24 | $24.7B | $14.2B |
负债/权益比EQTZTS
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.33× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1B | $893.0M |
| 自由现金流经营现金流 - 资本支出 | $1.9B | $732.0M |
| 自由现金流率自由现金流/营收 | 57.6% | 30.7% |
| 资本支出强度资本支出/营收 | 18.0% | 6.7% |
| 现金转化率经营现金流/净利润 | 2.05× | 1.48× |
| 过去12个月自由现金流最近4个季度 | $3.5B | $2.3B |
8季度趋势，按日历期对齐
经营现金流EQTZTS
| Q1 26 | $3.1B | — | ||
| Q4 25 | $1.1B | $893.0M | ||
| Q3 25 | $1.0B | $938.0M | ||
| Q2 25 | $1.2B | $486.0M | ||
| Q1 25 | $1.7B | $587.0M | ||
| Q4 24 | $756.3M | $905.0M | ||
| Q3 24 | $593.0M | $951.0M | ||
| Q2 24 | $322.0M | $502.0M |
自由现金流EQTZTS
| Q1 26 | $1.9B | — | ||
| Q4 25 | $512.7M | $732.0M | ||
| Q3 25 | $391.3M | $805.0M | ||
| Q2 25 | $692.1M | $308.0M | ||
| Q1 25 | $1.2B | $438.0M | ||
| Q4 24 | $164.7M | $689.0M | ||
| Q3 24 | $23.5M | $784.0M | ||
| Q2 24 | $-236.1M | $370.0M |
自由现金流率EQTZTS
| Q1 26 | 57.6% | — | ||
| Q4 25 | 21.5% | 30.7% | ||
| Q3 25 | 20.0% | 33.5% | ||
| Q2 25 | 27.1% | 12.5% | ||
| Q1 25 | 71.4% | 19.7% | ||
| Q4 24 | 10.1% | 29.7% | ||
| Q3 24 | 1.8% | 32.8% | ||
| Q2 24 | -26.5% | 15.7% |
资本支出强度EQTZTS
| Q1 26 | 18.0% | — | ||
| Q4 25 | 25.7% | 6.7% | ||
| Q3 25 | 32.0% | 5.5% | ||
| Q2 25 | 21.5% | 7.2% | ||
| Q1 25 | 28.7% | 6.7% | ||
| Q4 24 | 36.4% | 9.3% | ||
| Q3 24 | 44.4% | 7.0% | ||
| Q2 24 | 62.7% | 5.6% |
现金转化率EQTZTS
| Q1 26 | 2.05× | — | ||
| Q4 25 | 1.66× | 1.48× | ||
| Q3 25 | 3.03× | 1.30× | ||
| Q2 25 | 1.58× | 0.68× | ||
| Q1 25 | 7.19× | 0.93× | ||
| Q4 24 | 1.81× | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | 33.84× | 0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EQT
暂无分部数据
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
